Aliases & Classifications for Cocaine Abuse

MalaCards integrated aliases for Cocaine Abuse:

Name: Cocaine Abuse 12 51 14 69
Cocaine-Related Disorders 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:809
ICD10 32 F14.1
ICD9CM 34 305.6 305.60
MeSH 41 D019970
SNOMED-CT 64 78267003

Summaries for Cocaine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cocaine despite negative consequences.

MalaCards based summary : Cocaine Abuse, also known as cocaine-related disorders, is related to personality disorder and antisocial personality disorder. An important gene associated with Cocaine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Neuroscience. The drugs Dopamine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, uterus and placenta, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Cocaine Abuse

Diseases related to Cocaine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 personality disorder 30.1 DRD2 SLC6A3 SLC6A4
2 antisocial personality disorder 29.9 DRD2 SLC6A3 SLC6A4
3 alcohol abuse 29.9 DRD2 PRL SLC6A4
4 cocaine dependence 29.7 DBH DRD2 SLC6A3 SLC6A4
5 panic disorder 29.6 HTR3A SLC6A2 SLC6A4
6 substance abuse 29.4 DBH DRD2 PRL SLC6A3 SLC6A4
7 anxiety 29.4 HTR3A SLC6A2 SLC6A3 SLC6A4
8 attention deficit-hyperactivity disorder 29.0 DBH DRD2 SLC18A2 SLC6A2 SLC6A3 SLC6A4
9 migraine with or without aura 1 29.0 DBH DRD2 HTR3A SLC6A3 SLC6A4
10 alcohol dependence 28.5 DBH DRD2 HTR3A SLC18A2 SLC6A3 SLC6A4
11 schizophrenia 28.1 DBH DRD2 HTR3A PRL SLC18A2 SLC6A2
12 bipolar disorder 27.4 DBH DRD2 GRK3 HTR3A PRL SLC6A2
13 galactorrhea 10.4 DRD2 PRL
14 schizophreniform disorder 10.4 DRD2 PRL
15 alcohol use disorder 10.4 DRD2 SLC6A4
16 prolactin producing pituitary tumor 10.4 DRD2 PRL
17 periodic limb movement disorder 10.4 DRD2 SLC6A4
18 functioning pituitary adenoma 10.4 DRD2 PRL
19 bruxism 10.4 DRD2 SLC6A4
20 peripartum cardiomyopathy 10.4 DRD2 PRL
21 heroin dependence 10.3 DRD2 SLC6A3
22 rem sleep behavior disorder 10.3 SLC6A3 SNCA
23 alexithymia 10.3 DRD2 SLC6A4
24 intermittent explosive disorder 10.3 PRL SLC6A4
25 alcohol-induced mental disorder 10.3 DRD2 SLC6A3 SLC6A4
26 alcoholic psychosis 10.3 DRD2 SLC6A3 SLC6A4
27 pathological gambling 10.3 DRD2 SLC6A3 SLC6A4
28 separation anxiety disorder 10.2 PRL SLC6A3
29 autonomic dysfunction 10.2 DBH SNCA
30 amphetamine abuse 10.2 SLC6A2 SLC6A3
31 eating disorder 10.2 DRD2 SLC6A3 SLC6A4
32 striatonigral degeneration 10.2 DRD2 SLC6A3 SNCA
33 migraine without aura 10.2 DRD2 PRL SLC6A4
34 agoraphobia 10.2 SLC6A2 SLC6A4
35 substance dependence 10.2 DRD2 SLC6A3 SLC6A4
36 schizoaffective disorder 10.2 DRD2 PRL SLC6A4
37 supranuclear palsy, progressive, 1 10.2 DRD2 SLC6A3 SNCA
38 stuttering 10.2 DBH DRD2 SLC6A3
39 specific developmental disorder 10.2 SLC6A2 SLC6A3 SLC6A4
40 restless legs syndrome 10.2 DRD2 SLC6A3 SNCA
41 cerebritis 10.2
42 premature ejaculation 10.1 HTR3A SLC6A3 SLC6A4
43 autism spectrum disorder 10.1 DRD2 SLC6A3 SLC6A4
44 postpartum depression 10.1 PRL SLC6A4
45 tic disorder 10.1 DRD2 SLC18A2 SLC6A3
46 pure autonomic failure 10.1 DBH SNCA
47 myocardial infarction 10.0
48 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.0
49 ischemia 10.0
50 vasculitis 10.0

Comorbidity relations with Cocaine Abuse via Phenotypic Disease Network (PDN):


Alcohol Abuse

Graphical network of the top 20 diseases related to Cocaine Abuse:



Diseases related to Cocaine Abuse

Symptoms & Phenotypes for Cocaine Abuse

GenomeRNAi Phenotypes related to Cocaine Abuse according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.1 HTR3A SIGMAR1 SLC6A4
2 Decreased viability GR00381-A-3 9.1 HTR3A SIGMAR1 SLC6A4

MGI Mouse Phenotypes related to Cocaine Abuse:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.14 SLC6A3 HTR3A SLC6A4 PRL SNCA SIGMAR1
2 growth/size/body region MP:0005378 9.92 SLC6A2 DRD2 SLC6A3 HTR3A SLC6A4 SLC18A2
3 endocrine/exocrine gland MP:0005379 9.91 DRD2 SLC6A3 HTR3A SLC6A4 PRL DBH
4 homeostasis/metabolism MP:0005376 9.91 DRD2 SLC6A3 HTR3A SLC6A4 PRL SLC18A2
5 integument MP:0010771 9.81 SLC6A3 HTR3A SLC6A4 PRL SNCA SLC17A8
6 nervous system MP:0003631 9.65 SLC6A3 HTR3A SLC6A4 PRL SNCA SLC17A8
7 taste/olfaction MP:0005394 9.02 SLC6A3 GRK3 SNCA SLC18A2 DRD2

Drugs & Therapeutics for Cocaine Abuse

Drugs for Cocaine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 153)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 446220 5760
3
Risperidone Approved, Investigational Phase 4,Phase 2 106266-06-2 5073
4
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 300-62-9 3007 5826
5
Serotonin Phase 4,Phase 2,Phase 1 50-67-9 5202
6 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
8 Serotonin Agents Phase 4,Phase 2,Phase 1
9 Serotonin Antagonists Phase 4,Phase 2
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Tranquilizing Agents Phase 4,Phase 2,Phase 1,Early Phase 1
12 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Opiate Alkaloids Phase 4,Phase 2,Phase 1
16 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Antipsychotic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
22 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 Quetiapine Fumarate Phase 4 111974-72-2
24 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
25 Dopamine Antagonists Phase 4,Phase 2,Early Phase 1
26
Choline Approved, Nutraceutical Phase 3 62-49-7 305
27 Antidepressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antidepressive Agents, Second-Generation Phase 3,Phase 2,Phase 1
29 adderall Phase 2, Phase 3
30 Cytidine Diphosphate Choline Phase 3
31 Nootropic Agents Phase 3,Phase 2
32
Ondansetron Approved Phase 2 99614-02-5 4595
33
Citalopram Approved Phase 2,Phase 1 59729-33-8 2771
34
Methadone Approved Phase 2,Phase 1 76-99-3 4095
35
Modafinil Approved, Investigational Phase 2,Phase 1 68693-11-8 4236
36
Guaifenesin Approved, Investigational, Vet_approved Phase 2,Phase 1 93-14-1 3516
37
Armodafinil Approved, Investigational Phase 2,Phase 1 112111-43-0
38
Ethanol Approved Phase 2,Phase 1,Early Phase 1 64-17-5 702
39
Norepinephrine Approved Phase 2 51-41-2 439260
40
Tiagabine Approved, Investigational Phase 2 115103-54-3 60648
41
Baclofen Approved Phase 2,Early Phase 1 1134-47-0 2284
42
Levodopa Approved Phase 2,Phase 1 59-92-7 6047
43
Doxazosin Approved Phase 2,Phase 1 74191-85-8 3157
44
Donepezil Approved Phase 2 120014-06-4 3152
45
Galantamine Approved Phase 2 357-70-0 9651
46
Acetylcholine Approved Phase 2 51-84-3 187
47
Haloperidol Approved Phase 2 52-86-8 3559
48
Topiramate Approved Phase 2 97240-79-4 5284627
49
Disulfiram Approved Phase 2,Phase 1 97-77-8 3117
50
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386

Interventional clinical trials:

(show top 50) (show all 98)

# Name Status NCT ID Phase Drugs
1 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4 Quetiapine;Risperidone
2 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
3 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
4 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3 Nefazodone
5 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
6 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
7 Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8 Unknown status NCT00218036 Phase 2 Modafinil 200mg;Modafinil 400mg;Citalopram 20mg;Citalopram 40mg;Placebo
8 Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00218543 Phase 2 Atomoxetine
9 Disulfiram for Cocaine Abuse in Buprenorphine Treatment Completed NCT00913484 Phase 2 Disulfiram;Placebo
10 Pemoline for Cocaine Abuse - 7 Completed NCT00000282 Phase 2 Pemoline
11 Mazindol for Cocaine Abuse - 2 Completed NCT00000277 Phase 2 Mazindol
12 Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1 Completed NCT00000245 Phase 2 Desipramine
13 The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1 Completed NCT00158288 Phase 2
14 Disulfiram for Cocaine Abuse Completed NCT00395850 Phase 2 Disulfiram
15 Cocaine Abuse and ADHD - 10 Completed NCT00000275 Phase 2 Flupenthixol
16 IV Cocaine Abuse: A Laboratory Model - 4 Completed NCT00000215 Phase 2 Pergolide
17 IV Cocaine Abuse: A Laboratory Model - 3 Completed NCT00000214 Phase 2 Buprenorphine
18 IV Cocaine Abuse: A Laboratory Model - 2 Completed NCT00000213 Phase 2 Fluoxetine
19 IV Cocaine Abuse: A Laboratory Model - 1 Completed NCT00000212 Phase 2 Desipramine
20 Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse Completed NCT01953432 Phase 2 Doxazosin;Placebo
21 Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse Completed NCT00809835 Phase 2 Galantamine
22 New Approaches to Cocaine Abuse Medications (A) - 6 Completed NCT00000271 Phase 2 Desipramine;Placebo
23 Tryptophan and Behavior Therapy for Cocaine Abuse - 1 Completed NCT00000324 Phase 2 Tryptophan
24 Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9 Completed NCT00000274 Phase 2 Flupenthixol
25 Disulfiram for Treating Cocaine Dependence in Individuals Maintained on Methadone Completed NCT00218608 Phase 2 Disulfiram
26 Effects of Aripiprazole on Cocaine Craving and Self-Administration Completed NCT00373880 Phase 2 Aripiprazole + Cocaine;Placebo + Cocaine
27 A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse Completed NCT01846481 Phase 2 RBP-8000 100 mg;Placebo;Cocaine;RBP-8000 200 mg
28 Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6 Completed NCT00000303 Phase 2 Baclofen
29 Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4 Completed NCT00000301 Phase 2 Amantadine
30 Effectiveness of GABA Agonists in Reducing the Reinforcing Effects of Cocaine Completed NCT00218166 Phase 2 GABA Agonists
31 Medications for Stopping Cocaine Dependence and Preventing Relapse Completed NCT00218023 Phase 2 Modafinil;Levodopa/Carbidopa;Naltrexone HCl;Placebo
32 Use of Donepezil for Treatment of Cocaine Dependence Completed NCT00467389 Phase 2 Donepezil, 5 mg daily
33 Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence Completed NCT00218075 Phase 2 Levodopa;Carbidopa
34 Buprenorphine Maintenance for Opioid Addicts - 2 Completed NCT00000203 Phase 2 Buprenorphine
35 Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo Completed NCT00218348 Phase 2 Dextro-Amphetamine Sulfate
36 Therapeutic Substance Abuse Treatment in Pregnancy - 1 Completed NCT00227903 Phase 2
37 Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence Completed NCT00142818 Phase 2 Naltrexone;Modafinil;Placebo
38 Abstinence-Linked Money Management Multisite Completed NCT01327586 Phase 2
39 Contingency Management for Persons With Severe Mental Illness Completed NCT01478815 Phase 2
40 A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence Completed NCT00421603 Phase 2 Adderall-XR and Topiramate;Placebo
41 Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1 Completed NCT00129298 Phase 2 Tiagabine
42 New Medication Treatment for Stimulant Dependence Completed NCT00689572 Phase 2 Ondansetron;Placebo
43 Clinical Trial of Abstinence-Linked Money Management Completed NCT00536900 Phase 2
44 Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction Not yet recruiting NCT03423667 Phase 2 N-acetylcysteine;Lactose powder
45 Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1 Terminated NCT00000309 Phase 2 Risperidone
46 Glutaminergic Agents for Cocaine Abuse - 5 Completed NCT00000280 Phase 1 Nimodipine
47 Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2 Completed NCT00000316 Phase 1 Cocaine
48 Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1 Completed NCT00000315 Phase 1 Cocaine
49 Methylphenidate Treatment for Cocaine Abuse and ADHD - 1 Completed NCT00136734 Phase 1 Methylphenidate
50 Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin Completed NCT02393599 Phase 1 Lorcaserin;Placebo;Cocaine Infusion

Search NIH Clinical Center for Cocaine Abuse

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: cocaine-related disorders

Genetic Tests for Cocaine Abuse

Anatomical Context for Cocaine Abuse

MalaCards organs/tissues related to Cocaine Abuse:

38
Brain, Uterus, Placenta, Testes, Lung, Pituitary, Amygdala

Publications for Cocaine Abuse

Articles related to Cocaine Abuse:

(show top 50) (show all 590)
# Title Authors Year
1
Cocaine abuse: Longitudinal MR imaging of lasting diffused leukoencephalopathy. ( 29400600 )
2018
2
Moyamoya tipping point: fatal bilateral MCA territory infarction following cocaine abuse. ( 29351941 )
2018
3
Cocaine Abuse, Traumatic Brain Injury, and Preexisting Brain Lesions as Risk Factors for Bupropion-Associated Psychosis. ( 28590371 )
2017
4
The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic. ( 28266501 )
2017
5
Towards an automatic lab-on-valve-ion mobility spectrometric system for detection of cocaine abuse. ( 28712550 )
2017
6
Heparan sulfate: Resilience factor and therapeutic target for cocaine abuse. ( 29066725 )
2017
7
Internuclear Ophthalmoplegia Secondary to Cocaine Abuse. ( 28265477 )
2017
8
Quadricuspid Aortic Valve Or a Rare Complication of Cocaine Abuse? ( 29122430 )
2017
9
Botryoid nuclei resulting from cocaine abuse. ( 28439943 )
2017
10
Multi-System Complications after Intravenous Cocaine Abuse. ( 28507634 )
2017
11
Chronic orbital inflammatory disease and optic neuropathy associated with long-term intranasal cocaine abuse: 2 cases and literature review. ( 28812909 )
2017
12
A tip from the nose: rhinocerebral mucormycosis in a patient with alcoholic liver cirrhosis and cocaine abuse, an uncommon association. ( 28784893 )
2017
13
Cocaine abuse determination by ion mobility spectrometry using molecular imprinting. ( 28012589 )
2017
14
Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease. ( 28315271 )
2017
15
Impact on Cortical Function of Cocaine Abuse Co-Occurring with HIV. ( 27909321 )
2017
16
Resting state brain connectivity patterns before eventual relapse into cocaine abuse. ( 28057531 )
2017
17
The Use of Intraoperative Transesophageal Echocardiography in Thoracic Aortic Dissection Due to Chronic Cocaine Abuse. ( 28920034 )
2017
18
Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. ( 27600990 )
2016
19
Plant expression of cocaine hydrolase-Fc fusion protein for treatment of cocaine abuse. ( 27756365 )
2016
20
Increased MFG-E8 expression and its implications in the vascular pathophysiology of cocaine abuse. ( 27182119 )
2016
21
Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse. ( 27250583 )
2016
22
Extensive Necrotic Purpura in Levamisole-Adulterated Cocaine Abuse - A Case Report. ( 27500987 )
2016
23
Behaviour of hygrine and cuscohygrine in illicit cocaine production establishes their use as markers for chewing coca leaves in contrast with cocaine abuse. ( 27004438 )
2016
24
Cocaine abuse and effects in the serum levels of cytokines IL-6 and IL-10. ( 26679059 )
2016
25
Cocaine and crack cocaine abuse by pregnant or lactating mothers and analysis of its biomarkers in meconium and breast milk by LC-MS-A review. ( 26827634 )
2016
26
Plasma Selenium Levels in Chronic Cocaine Abuse. ( 27349018 )
2016
27
Cocaine abuse that presents with acute scrotal pain and mimics testicular torsion. ( 27583357 )
2016
28
Cocaine Abuse: An Unusual Association. ( 27805341 )
2016
29
The Ventral Pallidum: Proposed Integrator of Positive and Negative Factors in Cocaine Abuse. ( 27710789 )
2016
30
A case of iloperidone overdose in a 27-year-old man with cocaine abuse. ( 27570623 )
2016
31
Multiple Pyoderma Gangrenosum Ulcers Associated with Cocaine Abuse. ( 28003907 )
2016
32
Relationship between coronary artery ectasia, cocaine abuse and acute coronary syndromes. ( 27231522 )
2016
33
The most dangerous complication of intranasal cocaine abuse in a young man: cardiac arrest. ( 26778640 )
2015
34
Atraumatic splenic rupture and ileal volvulus following cocaine abuse. ( 26324218 )
2015
35
Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies. ( 25662894 )
2015
36
Neuropsychological impairments associated with the relation between cocaine abuse and violence: neurological facilitation mechanisms. ( 25879478 )
2015
37
Assessing cocaine abuse using LC-MS/MS measurements in biological specimens. ( 26168256 )
2015
38
Membranous glomerulonephritis and cellular crescents induced by levamisole-adulterated cocaine abuse: a case report. ( 26605317 )
2015
39
Identification of long noncoding RNAs dysregulated in the midbrain of human cocaine abusers. ( 26222413 )
2015
40
Investigating the potential influence of cause of death and cocaine levels on the differential expression of genes associated with cocaine abuse. ( 25658879 )
2015
41
Cocaine abuse, retiform purpura and antiphospholipid syndrome. ( 26070938 )
2015
42
Platelet Activation in Human Immunodeficiency Virus Type-1 Patients Is Not Altered with Cocaine Abuse. ( 26076359 )
2015
43
Cocaine Abuse in Later Life: A Case Series and Review of the Literature. ( 26445694 )
2015
44
The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. ( 26239290 )
2015
45
Impact of cocaine abuse on HIV pathogenesis. ( 26539167 )
2015
46
Prosthetic Management for a Palatal Perforation from Cocaine Abuse. ( 25557361 )
2015
47
Multiple gastrointestinal complications of crack cocaine abuse. ( 24839446 )
2014
48
Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. ( 24898775 )
2014
49
Acute coronary syndrome after levamisole-adultered cocaine abuse. ( 24365689 )
2014
50
Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects. ( 22026501 )
2014

Variations for Cocaine Abuse

Expression for Cocaine Abuse

Search GEO for disease gene expression data for Cocaine Abuse.

Pathways for Cocaine Abuse

GO Terms for Cocaine Abuse

Cellular components related to Cocaine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.85 DRD2 SIGMAR1 SLC18A2 SLC6A2 SLC6A3 SLC6A4
2 synapse GO:0045202 9.76 HTR3A SIGMAR1 SLC17A8 SNCA
3 membrane raft GO:0045121 9.65 SLC6A2 SLC6A3 SLC6A4
4 neuronal cell body GO:0043025 9.62 HTR3A SLC17A8 SLC6A3 SNCA
5 neuron projection GO:0043005 9.56 SLC17A8 SLC6A2 SLC6A3 SLC6A4
6 axon GO:0030424 9.46 DRD2 HTR3A SLC6A3 SNCA
7 nuclear outer membrane GO:0005640 9.4 SIGMAR1 SNCA
8 cytoplasmic vesicle GO:0031410 9.35 DBH DRD2 SIGMAR1 SLC17A8 SLC18A2
9 axon terminus GO:0043679 8.8 DRD2 SLC17A8 SNCA
10 plasma membrane GO:0005886 10.09 DRD2 GRK3 HTR3A SIGMAR1 SLC18A2 SLC6A2

Biological processes related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.93 HTR3A SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
2 response to drug GO:0042493 9.8 DRD2 SLC6A2 SLC6A3 SLC6A4 SNCA
3 response to ethanol GO:0045471 9.78 DRD2 HTR3A SLC6A3
4 response to toxic substance GO:0009636 9.74 DRD2 SLC18A2 SLC6A4
5 chemical synaptic transmission GO:0007268 9.72 DBH HTR3A SLC18A2 SLC6A2 SNCA
6 excitatory postsynaptic potential GO:0060079 9.69 DRD2 HTR3A SNCA
7 locomotory behavior GO:0007626 9.67 DBH DRD2 SLC18A2 SLC6A3
8 receptor internalization GO:0031623 9.66 GRK3 SNCA
9 response to nicotine GO:0035094 9.65 DRD2 SLC6A3
10 positive regulation of multicellular organism growth GO:0040018 9.65 DRD2 SLC6A3
11 associative learning GO:0008306 9.65 DBH DRD2
12 regulation of dopamine secretion GO:0014059 9.64 DRD2 SNCA
13 behavioral response to cocaine GO:0048148 9.64 DRD2 SNCA
14 response to iron ion GO:0010039 9.63 DRD2 SLC6A3
15 regulation of long-term neuronal synaptic plasticity GO:0048169 9.63 DRD2 SNCA
16 response to pain GO:0048265 9.62 DBH SLC6A2
17 synaptic transmission, dopaminergic GO:0001963 9.62 DRD2 SNCA
18 behavioral response to ethanol GO:0048149 9.61 DBH DRD2
19 response to amphetamine GO:0001975 9.61 DBH DRD2 SLC18A2
20 dopamine metabolic process GO:0042417 9.6 DRD2 SNCA
21 neurotransmitter biosynthetic process GO:0042136 9.59 SLC6A3 SLC6A4
22 ammonium transmembrane transport GO:0072488 9.58 SLC6A3 SLC6A4
23 prepulse inhibition GO:0060134 9.58 DRD2 SLC6A3
24 dopamine biosynthetic process GO:0042416 9.56 SLC6A3 SNCA
25 response to cocaine GO:0042220 9.56 DRD2 HTR3A SLC6A3 SNCA
26 neurotransmitter transport GO:0006836 9.55 SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
27 adenohypophysis development GO:0021984 9.54 DRD2 SLC6A3
28 dopamine catabolic process GO:0042420 9.52 DBH SLC6A3
29 dopamine transport GO:0015872 9.49 SLC18A2 SLC6A3
30 serotonin transport GO:0006837 9.48 SLC18A2 SLC6A4
31 monoamine transport GO:0015844 9.26 SLC18A2 SLC6A2 SLC6A3 SLC6A4
32 dopamine uptake involved in synaptic transmission GO:0051583 8.92 SLC6A2 SLC6A3 SLC6A4 SNCA
33 transport GO:0006810 10.09 HTR3A SIGMAR1 SLC17A8 SLC18A2 SLC6A2 SLC6A3

Molecular functions related to Cocaine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.5 DRD2 SIGMAR1 SLC6A3
2 beta-tubulin binding GO:0048487 9.46 SLC6A2 SNCA
3 symporter activity GO:0015293 9.46 SLC17A8 SLC6A2 SLC6A3 SLC6A4
4 alpha-tubulin binding GO:0043014 9.43 SLC6A2 SNCA
5 neurotransmitter:sodium symporter activity GO:0005328 9.4 SLC6A3 SLC6A4
6 dopamine binding GO:0035240 9.37 DRD2 SLC6A3
7 serotonin transmembrane transporter activity GO:0015222 9.26 SLC18A2 SLC6A4
8 dopamine:sodium symporter activity GO:0005330 9.13 SLC6A2 SLC6A3 SLC6A4
9 monoamine transmembrane transporter activity GO:0008504 8.92 SLC18A2 SLC6A2 SLC6A3 SLC6A4

Sources for Cocaine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....